Condition: Type 2 Diabetes Mellitus · Sponsor: AstraZeneca
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Huntsville, Alabama, United States | Not Yet Recruiting |
| Research Site | Mobile, Alabama, United States | Not Yet Recruiting |
| Research Site | Sheffield, Alabama, United States | Not Yet Recruiting |
| Research Site | Little Rock, Arkansas, United States | Not Yet Recruiting |
| Research Site | Bakersfield, California, United States | Not Yet Recruiting |
| Research Site | Los Angeles, California, United States | Not Yet Recruiting |
| Research Site | Ontario, California, United States | Not Yet Recruiting |
| Research Site | Lake City, Florida, United States | Not Yet Recruiting |
| Research Site | Lakeland, Florida, United States | Not Yet Recruiting |
| Research Site | Atlanta, Georgia, United States | Not Yet Recruiting |
| Research Site | Chicago, Illinois, United States | Not Yet Recruiting |
| Research Site | Skokie, Illinois, United States | Not Yet Recruiting |
+ 260 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07662109